<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691805</url>
  </required_header>
  <id_info>
    <org_study_id>tDCS-TUD</org_study_id>
    <nct_id>NCT03691805</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Stimulation - Tobacco Use Disorder</brief_title>
  <official_title>Transcranial Direct Current Stimulation as an Intervention in Tobacco Use Disorder: Effects on Consumption and Craving</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to detect how transcranial direct current stimulation (tDCS) affects smokers'&#xD;
      inhibitory control, craving and consumption of tobacco goods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participating smokers are to receive anodal transcranial direct current stimulation of the&#xD;
      right dorsolateral prefrontal cortex (rDLPFC) for 20 minutes on five consecutive days.&#xD;
      Neuropsychological tests on inhibitory control and interviews on smoking habits and craving&#xD;
      will be applied before and after the first stimulation as well as after the fifth&#xD;
      stimulation.&#xD;
&#xD;
      After a follow-up period of three days, smoking behaviour will be assessed in a telephone&#xD;
      interview.&#xD;
&#xD;
      Changes in inhibitory control and smoking behaviour will be compared between an active and a&#xD;
      sham stimulation group.This way the effects of transcranial direct current stimulation on&#xD;
      tobacco use disorder are to be clarified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Actual">February 18, 2020</completion_date>
  <primary_completion_date type="Actual">February 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Half of the participants will receive transcranial direct current stimulation, while the others will receive sham stimulation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be blinded as to their assigned study arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduced number of cigarettes smoked</measure>
    <time_frame>First assessment on Day 1, second on Day 8</time_frame>
    <description>Smoking habits will be assessed via interview at the beginning of the study and after a follow-up period of three days. Number of cigarettes smoked will be compared longitudinally and between groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduced Carving</measure>
    <time_frame>First assessment on Day 1, second on Day 5, third on Day 8</time_frame>
    <description>Craving will be assessed using visual analog scales on the first and fifth day of the study as well as in the follow-up interview. Ratings will be compared longitudinally and between groups..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increased inhibitory control</measure>
    <time_frame>First and second testing on Day 1, third testing on Day 5</time_frame>
    <description>Inhibitory control will be assessed in neuropsychological tests (Go / No-Go, Stop-Signal Task) before and after the first stimulation session and after the fifth session. Results will be compared longitudinally and between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>anodal tDCS over rDLPFC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal Cortex (DLPFC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will receive sham tDCS (transcranial direct current stimulation) of the DLPFC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <description>The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.</description>
    <arm_group_label>anodal tDCS over rDLPFC</arm_group_label>
    <other_name>sooma medical</other_name>
    <other_name>transcranial direct current stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.</description>
    <arm_group_label>sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  tobacco use disorder&#xD;
&#xD;
          -  normal or correctable eyesight&#xD;
&#xD;
          -  sufficient ability to communicate with the investigators, to answer questions in oral&#xD;
             and written form&#xD;
&#xD;
          -  fully informed consent&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  withdrawal of the declaration of consent&#xD;
&#xD;
          -  exclusion criteria for tDCS (metal implants in the head, acute eczema, known epilepsy)&#xD;
&#xD;
          -  severe internal, neurological or psychiatric comorbidity&#xD;
&#xD;
          -  pharmacotherapy with psychoactive substances within the last 14 days&#xD;
&#xD;
          -  axis-I disorder according to ICD-10 and DSM 5 (except tobacco use disorder)&#xD;
&#xD;
          -  positive urin drug screening (cannabis, amphetamine, opiates, benzodiazepines,&#xD;
             cocaine)&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Vollst채dt-Klein</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZI Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik f체r Abh채ngiges Verhalten, Zentralinstitut f체r Seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

